<DOC>
	<DOCNO>NCT01153841</DOCNO>
	<brief_summary>The purpose study evaluate safety reactogenicity Synflorix™ ( GSK 1024850A ) give 3-dose primary immunization course co-administered Infanrix hexa™ vaccine 2 , 3 4 month age infant Vietnam .</brief_summary>
	<brief_title>Primary Vaccination Study With GSK Biologicals ' Pneumococcal Vaccine Healthy Infants Vietnam</brief_title>
	<detailed_description />
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Male female subject , include 612 week age time first vaccination . Subjects investigator believe parents/guardians comply requirement protocol . Written sign thumbprinted informed consent obtain parent ( ) /LAR child . Where parent ( ) /guardian ( ) illiterate , consent form countersign witness . Free obvious health problem establish medical history clinical examination enter study . Use investigational nonregistered product study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Acute disease and/or fever time enrolment . History reaction hypersensitivity likely exacerbate component vaccine ( ) . History chronic condition ( ) require treatment cancer autoimmune disease . Hypersensitivity latex . Previous vaccination diphtheria , tetanus , pertussis , Hemophilus influenzae type b and/or Streptococcus pneumoniae . Locally recommend EPI vaccine give birth allow , administer least one month first dose study vaccine administer . Other locally recommend vaccine allow , even concomitantly administer study vaccine , document eCRF .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pneumococcal vaccine</keyword>
</DOC>